His clinical features favored a diagnosis of "clinically considerable overlap in their clinical, neuropathological probable PSP" based on NINDS mandatory inclusion and genetic features.
[1] The magnetic resonance imaging criteria. [2] His MRI also showed severe midbrain atrophy (MRI) findings of asymmetric fronto-parietal atrophy in with an anteroposterior diameter of 11 mm, thinning of CBD and severe midbrain atrophy in PSP are the most tectal plate and hyperintensities in the periaqueductal grey consistent and useful means to differentiate between them area [ Figure 1 ], which are characteristic of PSP. during life. [2] We present an unusual case that showed Interestingly, his MRI also showed asymmetric left parietal radiological features of both conditions. atrophy [ Figure 2 ], which is a radiological NINDS exclusion criterion for PSP but is well known in CBD. [2] Case Report
A 69-year-old right-handed man presented to us with gradual onset of slowness of all movements and abnormal posturing of his right hand and leg for two years. The abnormal postures were flexion at his right wrist and extension of his right big toe while walking. Six months later he started falling backwards. He later developed slurring of speech, pseudo bulbar affect and precipitancy of micturition. He gave no history of rest or action tremor, involuntary jerks of limbs, alien hand phenomenon, cognitive decline, ataxia, postural syncope or impotence. He had no psychiatric symptoms. His family history was negative for any neurological illness. He was a diabetic, There were no infarcts or gliotic regions in the brain. He had no previous CT or MRI study of the brain or MRI study of the brain.
Discussion
Our patient had clinical features that were sufficient to diagnose PSP, consisting of progressive levodopa unresponsive parkinsonism with vertical supranuclear gaze palsy, prominent postural instability with falls within one year of onset of illness and no evidence of other diseases which could explain these. [3] Asymmetric signs and dystonia which were seen in our patient are known to occur in about 27% of patients with PSP and dystonia 
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( w w w may even be a presenting feature of PSP. [4] Our patient also had focal parietal atrophy which is an exclusion criterion for PSP. There were no other causes for focal cortical atrophy in him. Moderate to severe diffuse cortical far. Long-term follow-up of this patient for signs of cortical involvement and MRI evidence of progressive cortical atrophy may further assist clinical diagnostic classification as CBD. Diagnostic confirmation will need autopsy.
Progressive supranuclear palsy and CBD are also known to have overlap in their pathological and genetic features. The characteristic microscopic feature of PSP is argyrophillic tau reactive globose neurofibrillary tangles (NFT) and achromatic ballooned neurons in CBD. However, swollen neurons in the cortex are also described in PSP. [11] Neuronal inclusions in CBD can closely resemble globose type NFT of PSP and show tau positivity and basophilia but they are not ubiquitin-positive.
[12]
Progressive supranuclear palsy and CBD are classified as 'tauopathies' and are further linked by the predominance of four repeat (4-R) isoforms in neuronal and glial taupositive inclusions.
[13] Further overlap was shown by identical H1 and H1/H1 tau haplotype in CBD and PSP The recent report documenting occurrence of CBD and PSP in two individuals in a single family who presented with corticobasal syndrome and had other affected siblings with clinical PSP supports a unifying genetic etiology behind these 'tauopathies'.
[15] favor a diagnosis of CBD. [9] Absence of any cortical signs makes it difficult to diagnose typical CBD in our case using any of the existing clinical criteria. Early vertical gaze palsy is considered an exclusion factor for CBD based on one of the criteria. [6] Even if the phenotype in our patient is considered atypical CBD, the occurrence of MRI features of both diseases in the same patient makes our case unique. Slight midbrain atrophy has been reported in two patients with a clinical diagnosis of CBD.
[10]
Marked midbrain atrophy as in our case is not known so . [14] atrophy is usually seen in MRI in PSP. Focal parietal cortical atrophy has not been reported in MRI in patients with clinically diagnosed PSP though pathologically, parietal cortical volume loss is known in PSP. [5] An alternative diagnosis of CBD could also be considered in our patient based on the asymmetry and dystonia. Early falls can occur in those with foot dystonia. Although oculomotor apraxia with normal saccadic velocity is an early eye sign in CBD, eventually, supranuclear gaze palsy indistinguishable from PSP can occur in CBD. Pathologically proven CBD is known to have a phenotype identical to PSP. [1] There are no validated criteria to diagnose CBD similar to those for PSP, though a few have been proposed. [6] [7] [8] Litvan and colleagues have identified that lateralized motor signs (such as asymmetric parkinsonism, dystonia or myoclonus) and cognitive signs (ideomotor apraxia, aphasia or alien limb phenomenon) ) .
